Related Experiment Video

Updated: May 10, 2026

In vivo Evaluation of Mucociliary Clearance in Mice
06:35

In vivo Evaluation of Mucociliary Clearance in Mice

Published on: December 18, 2020

Inhaled mucoactive drugs for treating non-cystic fibrosis bronchiectasis in children

D Snijders1, S Calgaro, I Bertozzi

  • 1Pediatrics Department, University of Padua, Italy.

International Journal of Immunopathology and Pharmacology
|June 13, 2013
PubMed

Insights

This review found limited evidence for inhaled mucoactive agents in treating non-cystic fibrosis bronchiectasis (nCFb), especially in children. More research is needed to establish effective mucociliary clearance therapies for nCFb patients.

Area of Science:

  • Pulmonology
  • Respiratory Medicine
  • Pharmacology

Background:

  • Non-cystic fibrosis bronchiectasis (nCFb) is an acquired respiratory condition often treated with antibiotics and chest physiotherapy.
  • Impaired mucociliary clearance is a key mechanism in nCFb, leading to the use of inhaled mucoactive agents.
  • Commonly used agents include N-acetylcysteine, hypertonic saline (HS), mannitol, and recombinant human DNase (rhDNase).

Discussion:

  • A literature review (1992-present) identified 88 articles, with only 12 meeting selection criteria for nCFb treatment.
  • Evidence for rhDNase in pediatric nCFb is scarce (2 papers, 2 reviews).
  • Adult nCFb studies include 3 trials on HS, 5 on mannitol, and 2 on rhDNase, showing some effects.

Key Insights:

  • No observational or randomized controlled trials (RCTs) specifically address inhaled mucoactive drugs for pediatric nCFb.
  • Existing studies on adult nCFb patients using HS, mannitol, or rhDNase provide preliminary evidence of efficacy.
  • The current evidence base for treating nCFb with inhaled mucoactive agents is limited, particularly in children.

Outlook:

  • Further research, including robust clinical trials, is essential to evaluate the effectiveness of inhaled mucoactive drugs in children with nCFb.
  • Developing targeted therapies to improve mucociliary clearance in nCFb is a critical area for future investigation.
  • The findings highlight the need for more evidence-based treatment guidelines for nCFb, especially for pediatric populations.

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Related Concept Videos

Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...